Trial Profile

A phase II study of docetaxel and gemcitabine as a second line chemotherapy in cervical cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
Indications Cervical cancer
Focus Therapeutic Use
Acronyms SCOTSERV

Most Recent Events

30 Jan 2014 Accrual to date is 92% according to United Kingdom Clinical Research Network.
07 Apr 2009 Company added as trial sponsor as reported by United Kingdom Clinical Research Network.
07 Apr 2009 Planned end date changed from 31 Dec 2007 to 12 Feb 2009 as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com